ExodusPoint Capital Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-4,802
Closed -$833K 1666
2025
Q4
$833K Sell
4,802
-6,348
-57% -$1.16M 0.01% 1057
2025
Q3
$2.12M Buy
+11,150
New +$1.98M 0.02% 717
2024
Q4
Sell
-254,598
Closed -$39.5M 1635
2024
Q3
$39.5M Buy
254,598
+128,314
+102% +$19.2M 0.24% 63
2024
Q2
$17.3M Buy
+126,284
New +$17.3M 0.12% 151
2024
Q1
Sell
-93,700
Closed -$12.9M 1590
2023
Q4
$12.9M Buy
93,700
+60,309
+181% +$7.93M 0.08% 170
2023
Q3
$4.07M Sell
33,391
-50,625
-60% -$6.75M 0.04% 427
2023
Q2
$11.8M Buy
84,016
+21,192
+34% +$2.92M 0.1% 214
2023
Q1
$8.89M Buy
62,824
+50,332
+403% +$7.2M 0.07% 317
2022
Q4
$1.95M Sell
12,492
-17,704
-59% -$2.54M 0.03% 654
2022
Q3
$3.71M Sell
30,196
-12,902
-30% -$1.7M 0.05% 515
2022
Q2
$5.73M Buy
43,098
+23,425
+119% +$3.19M 0.07% 363
2022
Q1
$2.69M Sell
19,673
-13,806
-41% -$1.92M 0.03% 639
2021
Q4
$5.79M Sell
33,479
-2,020
-6% -$307K 0.06% 381
2021
Q3
$5.16M Buy
35,499
+20,943
+144% +$3.06M 0.07% 387
2021
Q2
$1.92M Buy
14,556
+2,749
+23% +$360K 0.02% 703
2021
Q1
$1.51M Sell
11,807
-11,651
-50% -$1.44M 0.02% 693
2020
Q4
$2.79M Buy
23,458
+12,208
+109% +$1.49M 0.03% 417
2020
Q3
$1.29M Buy
11,250
+642
+6% +$75.9K 0.03% 577
2020
Q2
$1.21M Buy
10,608
+5,335
+101% +$566K 0.03% 647
2020
Q1
$423K Buy
+5,273
New +$546K 0.02% 548

Other funds holding DGX

ExodusPoint Capital Management's DGX Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 4,802 shares — an estimated $833K sold.

ExodusPoint Capital Management first reported a position in DGX in Q1 2020 and held it in 20 quarters. The position peaked at $39.5M in Q3 2024. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 4,802 Quest Diagnostics shares in Q1 2026, an estimated $833K.
  • ExodusPoint Capital Management first reported a position in Quest Diagnostics in Q1 2020 and held it in 20 quarters.
  • ExodusPoint Capital Management's Quest Diagnostics position peaked at $39.5M in Q3 2024.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.